Pediatrix Medical Group stock has November 2 results date for Pediatrix Medical Group stock

Published on 10/01/2026 at 12:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 487.78 million, up 4.00 percent year over year. Pediatrix Medical Group stock has six analyst ratings.

MD, US59271J1051, Illustration mit AI erstellt.

Pediatrix Medical Group stock has a November 2, 2026, earnings date listed by Cayman Journal. The upcoming report will follow second-quarter revenue of USD 487.78 million and adjusted EBITDA of USD 76.4 million.

Revenue growth meets volume pressure

Yahoo Finance reported on September 22, 2026, that second-quarter 2026 net revenue rose 4.00 percent year over year to USD 487.8 million. Same-unit revenue from reimbursement-related factors also rose 4.00 percent, while patient volume declined 2.10 percent.

The operating mix explains the contrast. Adjusted EBITDA increased to USD 76.4 million from USD 73.2 million, a 4.37 percent improvement, as stronger revenue-cycle collections, payer mix and patient acuity offset lower volumes. The company expects full-year 2026 adjusted EBITDA of USD 280 million to USD 300 million, according to the same earnings-call transcript.

Analyst view stays cautious

MarketBeat reported on September 25, 2026, that six research firms held an average Hold rating, with five Hold ratings and one Buy rating. The average 12-month target was USD 26.60.

The second-quarter result exceeded the USD 478.49 million consensus revenue estimate by 1.94 percent. Reported earnings per share of USD 0.63 also exceeded the USD 0.59 consensus by 6.78 percent, giving the scheduled November report a clear comparison base.

Stock remains near yearly high

MD was last at USD 25.73 on the NYSE on September 30, 2026, at 4:00 p.m. ET. The quoted market capitalization was USD 2.1 billion, while the 52-week range was USD 15.70 to USD 27.94.